Genome editing company Editas, backed by Alphabet and Partners Healthcare, has secured $94.4m, pricing the initial public offering at the bottom of the $16 to $18 range.

Sheffield University spinout Diurnal began trading on Aim, on Christmas eve, raising $44.6m.

Novo and AbbVie-backed Reata plans to use the proceeds to fund a series of clinical trials for its hypertension treatments.

The oncology-focused biotechnology company, backed by Fidelity Management and Research, withdrew a previous filing in January 2015.

The energy management software producer has listed on the Australian Securities Exchange, providing an exit to Siemens and corporate-backed Aster Capital.

Clean hydrogen and graphite production moves closer as Hazer is officially admitted to the Australian Securities Exchange.

The marketing and game publishing company, which counts NetEase, Shanghai Media and Golden Eagle Broadcasting among its backers, has gone public in its home country of China.

The Visa and Starbucks-backed payment technology provider priced its shares at $9, a good deal below the $11 to $13 range set earlier this month.